• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Ophthalmologist perceptions regarding treatment of moderate to severe dry eye: results of a physician survey.眼科医生对中重度干眼症治疗的看法:一项医生调查的结果
Trans Am Ophthalmol Soc. 2009 Dec;107:205-10.
2
Ophthalmologist perceptions regarding treatment of moderate-to-severe dry eye: results of a physician survey.眼科医生对中重度干眼治疗的看法:一项医生调查的结果。
Eye Contact Lens. 2010 Jan;36(1):33-8. doi: 10.1097/ICL.0b013e3181c739ad.
3
Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease.蒸发型干眼疾病中泪液细胞因子和趋化因子分析及其与临床的相关性
Mol Vis. 2010 May 19;16:862-73.
4
Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye.干眼病情进展(PROOF)自然史研究的研究设计与基线研究结果
BMC Ophthalmol. 2017 Dec 28;17(1):265. doi: 10.1186/s12886-017-0646-5.
5
Long-term Natural History of Dry Eye Disease from the Patient's Perspective.从患者角度看干眼症的长期自然史
Ophthalmology. 2016 Feb;123(2):425-433. doi: 10.1016/j.ophtha.2015.10.011. Epub 2015 Nov 21.
6
Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey.美国患者报告的干眼疾病负担:一项在线横断面调查的结果。
Am J Ophthalmol. 2020 Aug;216:7-17. doi: 10.1016/j.ajo.2020.03.044. Epub 2020 Apr 8.
7
Ocular surface health in Shanghai University students: a cross-sectional study.上海大学生的眼表健康:一项横断面研究。
BMC Ophthalmol. 2018 Sep 12;18(1):245. doi: 10.1186/s12886-018-0825-z.
8
Depressive symptoms, resilience, and personality traits in dry eye disease.干眼症中的抑郁症状、心理弹性和人格特质
Graefes Arch Clin Exp Ophthalmol. 2019 Mar;257(3):591-599. doi: 10.1007/s00417-019-04241-1. Epub 2019 Jan 15.
9
Physician management of moderate-to-severe acute pain: results from the Physicians Partnering Against Pain (P³) study.医生对中重度急性疼痛的管理:来自医生对抗疼痛合作组织(P³)研究的结果。
J Opioid Manag. 2013 Nov-Dec;9(6):401-6. doi: 10.5055/jom.2013.0182.
10
Dry Eye Disease: Early Recognition with Guidance on Management and Treatment for Primary Care Family Physicians.干眼症:基层医疗家庭医生的早期识别及管理与治疗指南
Ophthalmol Ther. 2020 Dec;9(4):877-888. doi: 10.1007/s40123-020-00308-z. Epub 2020 Oct 22.

引用本文的文献

1
Performance and Safety of a Sodium Hyaluronate Tear Substitute with Polyethylene Glycol in Dry Eye Disease: A Multicenter, Investigator-Masked, Randomized, Noninferiority Trial.聚乙二醇玻璃酸钠在干眼症中的疗效和安全性:一项多中心、研究者设盲、随机、非劣效性临床试验。
J Ocul Pharmacol Ther. 2022 Nov;38(9):607-616. doi: 10.1089/jop.2022.0048. Epub 2022 Oct 21.
2
Trends in Dry Eye Disease Management Worldwide.全球干眼症治疗趋势
Clin Ophthalmol. 2021 Jan 14;15:165-173. doi: 10.2147/OPTH.S281666. eCollection 2021.
3
Lifitegrast: A novel drug for treatment of dry eye disease.lifitegrast:一种治疗干眼病的新型药物。
J Pharmacol Pharmacother. 2016 Oct-Dec;7(4):194-198. doi: 10.4103/0976-500X.195920.
4
Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.lifitegrast的研发:一种用于治疗干眼病的新型T细胞抑制剂。
Clin Ophthalmol. 2016 Jun 10;10:1083-94. doi: 10.2147/OPTH.S110557. eCollection 2016.
5
Expert opinion in the management of aqueous Deficient Dry Eye Disease (DED).水液缺乏型干眼症(DED)的管理专家意见。
BMC Ophthalmol. 2015 Oct 13;15:133. doi: 10.1186/s12886-015-0122-z.
6
Modulation of HLA-DR in dry eye patients following 30 days of treatment with a lubricant eyedrop solution.使用润滑眼药水溶液治疗30天后干眼患者体内人类白细胞抗原-DR的调节
Clin Ophthalmol. 2015 Jun 24;9:1137-45. doi: 10.2147/OPTH.S81355. eCollection 2015.

本文引用的文献

1
Evaluation of the stability and validity of participant samples recruited over the Internet.对通过互联网招募的参与者样本的稳定性和有效性进行评估。
Cyberpsychol Behav. 2008 Dec;11(6):743-5. doi: 10.1089/cpb.2007.0254.
2
Advances in understanding and managing dry eye disease.干眼症诊治的进展
Am J Ophthalmol. 2008 Sep;146(3):350-356. doi: 10.1016/j.ajo.2008.05.016. Epub 2008 Jul 2.
3
Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007).干眼症的管理与治疗:国际干眼症研讨会管理与治疗小组委员会报告(2007年)
Ocul Surf. 2007 Apr;5(2):163-78. doi: 10.1016/s1542-0124(12)70085-x.
4
The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007).干眼病的流行病学:国际干眼病研讨会流行病学小组委员会报告(2007年)
Ocul Surf. 2007 Apr;5(2):93-107. doi: 10.1016/s1542-0124(12)70082-4.
5
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007).干眼疾病的定义与分类:国际干眼研讨会定义与分类小组委员会报告(2007年)
Ocul Surf. 2007 Apr;5(2):75-92. doi: 10.1016/s1542-0124(12)70081-2.

眼科医生对中重度干眼症治疗的看法:一项医生调查的结果

Ophthalmologist perceptions regarding treatment of moderate to severe dry eye: results of a physician survey.

作者信息

Asbell Penny A, Spiegel Scott

机构信息

Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York, USA.

出版信息

Trans Am Ophthalmol Soc. 2009 Dec;107:205-10.

PMID:20126496
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2814567/
Abstract

PURPOSE

To understand ophthalmologists' current perceptions and treatment of patients with moderate to severe dry eye syndrome (DED).

METHODS

An online survey was distributed to 7,882 ophthalmologists, including 51 corneal specialists, throughout the United States from October 9 to 21, 2008. The response rate was 3.1% (n = 245), typical for this type of survey. Those who treated 4 or more patients with moderate to severe DED per month (235 of 245 [96%]) were asked to complete the survey.

RESULTS

Ninety-four percent of respondents agreed that more treatment options are needed for moderate to severe DED. Corneal specialists were more likely to strongly agree (63%) than general ophthalmologists (54%). Only 33% overall felt that current therapies were extremely or very effective for moderate DED, and only 5% for severe disease. Ninety-two percent agreed that multiple therapeutic agents are needed to manage moderate to severe DED. The respondents reported prescribing, recommending, or suggesting a mean of 3.2 different treatment approaches over the course of a year for patients with moderate DED and 4.9 for patients with severe DED. The most highly ranked goals in treatment of moderate to severe DED were maintaining and protecting the ocular surface (ranked 1 or 2 by 74%) and lubricating and hydrating the ocular surface (ranked 1 or 2 by 67%). Corneal specialists ranked maintaining and protecting the ocular surface even higher (ranked 1 or 2 by 82%).

CONCLUSIONS

Results reflected the difficulty of treating more serious moderate to severe cases, the importance of using multiple treatment approaches, the limitations of current treatment options, and the need for additional treatment options.

摘要

目的

了解眼科医生对中重度干眼综合征(DED)患者的当前认知及治疗情况。

方法

2008年10月9日至21日,一项在线调查在美国7882名眼科医生中展开,其中包括51名角膜专科医生。回复率为3.1%(n = 245),这在这类调查中较为典型。要求那些每月治疗4例或更多中重度DED患者的医生(245名中的235名[96%])完成调查。

结果

94%的受访者认为中重度DED需要更多的治疗选择。角膜专科医生比普通眼科医生更有可能强烈认同这一点(分别为63%和54%)。总体而言,只有33%的人认为当前疗法对中度DED极其或非常有效,对重度DED仅为5%。92%的人同意需要多种治疗药物来治疗中重度DED。受访者报告称,在一年中,他们为中度DED患者平均开出、推荐或建议3.2种不同的治疗方法,为重度DED患者平均开出4.9种。治疗中重度DED的最高目标是维持和保护眼表(74%的人将其排在第1或第2位)以及润滑和保湿眼表(67%的人将其排在第1或第2位)。角膜专科医生对维持和保护眼表的排名更高(82%的人将其排在第1或第2位)。

结论

结果反映了治疗更严重的中重度病例的困难、采用多种治疗方法的重要性、当前治疗选择的局限性以及对更多治疗选择的需求。